STERIS signs $1.6 billion revolving credit facility and $500 million delayed draw term loan
On November 4, 2026, STERIS and its subsidiaries entered a new $1.6 billion revolving credit facility that replaces the existing credit agreement dated October 7, 2024, and a separate delayed draw term loan of up to $500 million. The term loan can be drawn only if STERIS completes its acquisition of Xodus Medical, Inc. For shareholders, the filing adds committed borrowing capacity tied to that acquisition, and the filing does not state the acquisition price or the amount that will be borrowed.
Key points
- Revolving credit facility of $1,600 million matures on November 4, 2031, with an incremental increase of up to $800 million available.
- Delayed draw term loan of up to $500 million can be used only after the Xodus Medical Acquisition is consummated and terminates if that deal is validly terminated or the outside date occurs.
- Term loan matures five years after the acquisition closing date; no principal is due in year one, then 1.25% quarterly in years two and three and 1.875% quarterly in years four and five.
- No borrowings were incurred to refinance the existing credit agreement at closing, and all term loan lenders are also lenders under the revolver.
The filing
Written by AI on Nov 7, 2026, 11:17 PM ET, from this filing only.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.